Amyloid-β Production

Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders: Second Edition

Volumn , Issue , 2011, Pages 92-96

  Masters, Colin L ^a   Beyreuther, Konrad ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

A amyloid; Alzheimer's disease; Secretase

Indexed keywords

EID: 84876341692     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444341256.ch11     Document Type: Chapter

References (37)

1. Querfurth HW, La Ferla FM. Alzheimer's Disease. N Engl J Med 2010; 362: 329-344.
2. Bergmans BA, de Strooper B. γ-s ecretases: from cell biology to therapeutic strategies. Lancet Neurol 2010; 9: 215-226.
3. Pike KE, Savage G, Villemagne VL et al. ß-a myloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007; 130: 2837-2844.
4. Weller RO, Love S, Nicoll JA. Elimination of amyloid-ß from the brain, its failure in Alzheimer's disease and implications for therapy. In: Dickson DW (ed) Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders, 2nd edn. Oxford: Wiley-Blackwell, 2010.
5. Gasparini L, Gouras GK, Wang R. Stimulation of ß-amyloid precursor protein trafficking by insulin reduces intraneuronal ß-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci 2001; 21: 2561-2570.
6. Fitzjohn SM, Morton RA, Kuenzi F et al. Age-related impairment of synaptic transmission but normal long-term potentiation in transgenic mice that overexpress the human APP695SWE mutant form of amyloid precursor protein. J Neurosci 2001; 21: 4691-4698.
7. Vassar R, Kovacs DM, Yan R, Wong PC. The ß-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J Neurosci 2009; 29: 12787-12794.
8. Weidemann A, Eggert S, Reinhard FB et al. A novel e-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing. Biochemistry 2002; 41: 2825-2835.
9. Grziwa B, Grimm MOW, Masters CL, Beyreuther K, Hartmann T, Lichtenthaler SF. The transmembrane domain of the amyloid precursor protein in microsomal membranes is on both sides shorter than predicted. J Biol Chem 2003; 278: 6803-6908.
10. Lichtenthaler SF, Beher D, Grimm HS et al. The intramembrane cleavage site of the amyloid precursor protein depends on the length of its transmembrane domain. Proc Natl Acad Sci USA 2002; 99: 1365-1370.
11. Godemann R, Madden J, Krämer J et al. Fragment-based discovery of BACE1 inhibitors using functional assays. Biochemistry 2009; 48: 10743-10751.
12. Martone RL, Zhou H, Atchison K et al. Begacestat (GSI-953): A novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein γ-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther 2009; 331: 598-608.
13. Fassbender K, Simons M, Bergmann C et al. Simvastatin strongly reduces levels of Alzheimer's disease ß-amyloid peptides A ß 42 and A ß 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98: 5856-5861.
14. Shelton CC, Zhu L, Chau D et al. Modulation of γ-secretase specifi-city using small molecule allosteric inhibitors. Proc Natl Acad Sci USA 2009; 106: 20228-20233.
15. Scheuermann S, Hambsch B, Hesse L et al. Homodimerization of amyloid precursor protein and its implication in the amyloidogenic pathway of Alzheimer's dlsease. J Biol Chem 2001; 276: 33923-33929.
16. Eggert S, Midthune B, Cottrell B, Koo EH. Induced dimerization of the amyloid precursor protien leads to decreased amyloid-ß protein production. J Biol Chem 2009; 284: 28943-28952.
17. Tõugu V, Karafin A, Zovo K et al. Zn(II)-and Cu(II)-induced non-fibrillar aggregates of amyloid-ß (1-42) peptide are transformed to amyloid fibrils, both spontaneously and under the influence of metal chelators. J Neurochem 2009; 110: 1784-1795.
18. McLean CA, Cherny RA, Fraser FW et al. Soluble pool of A ß amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999; 46: 860-866.
19. Bush Al, Pettingell WH Jr, Paradis MD, Tanzi RE. Modulation of A ß adhesiveness and secretase site cleavage by zinc. J Biol Chem 1994; 269: 12152-12158.
20. Curtain CC, Ali F, Volitakis I et al. Alzheimer's disease amyloid-ß binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem 2001; 276: 20466-20473.
21. Pratico D, Uryu K, Leight S, Trojanoswki JQ, Lee VM. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 2001; 21: 4183-4187.
22. Noguchi A, Matsumura S, Dezawa M et al. Isolation and characterization of patient-derived, toxic, high mass amyloid ß-protien (A ß) assembly from Alzheimer disease brains. J Biol Chem 2009; 284: 32895-32905.
23. Ono K, Condron MM, Teplow DB. Structure-neurotoxicity relationship of amyloid ß-protein oligomers. Proc Natl Acad Sci USA 2009; 106: 14745-14750.
24. Adlard PA, Cherny RA, Finkelstein DI et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial A ß. Neuron 2008; 59: 43-55.
25. Lannfelt L, Blennow K, Zetterberg H et al., on behalf of the PBT2-201-EURO Study Group. Safety, efficacy and biomarker findings of PBT2 in targeting A ß as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2008; 7: 779-786. [See also Erratum. Lancet Neurol 2009, 8: 981.]
26. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A ß antibody alters CNS and plasma A ß clearance and decreases brain A ß burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001; 98: 8850-8855.
27. Bates KA, Verdile G, Li Q-X et al. Clearance machanisms of Alzheimer's amyloid-ß peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatr 2009; 14: 469-486.
28. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 2009; 10: 333-344.
29. Rowe CC, Ackerman U, Browne W et al. Imaging of amyloid ß in Alzheimer's disease with 18 F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008; 7: 129-135.
30. Rinne JO, Brooks DJ, Rossor MN et al. 11C-PiB PET assessment of change in fibrillar amyloid-ß load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010; 9 (4): 363-372.
31. Andreasen N, Minthon L, Davidsson P et al. Evaluation of CSF-tau and CSF-A ß 42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001; 58: 373-379.
32. Craig-Schapiro R, Fagan AM, Holtzman DM. Biomarkers of Alzheimer's disease. Neurobiol Dis 2009; 35: 128-140.
33. Fjell AM, Walhovd KB, Fennema-Notestine C et al. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. J Neurosci 2010; 30: 2088-2101.
34. Jagust WJ, Landau SM, Shaw LM et al. Relationships between biomarkers in aging and dementia. Neurology 2009; 73: 1193-1199.
35. Götz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by A ß 42 fibrils. Science 2001; 293: 1491-1495.
36. Lewis J, Dickson DW, Lin WL et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001; 293: 1487-1491.
37. Rhein V, Song X, Wiesner A et al. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci USA 2009; 106: 20057-20062.